ACE BioSciences
From Biocompany.net
http://www.acebiosciences.com/ACE BioSciences was founded in 2001. The company is based in Odense, Denmark, the leading proteomics cluster in Europe.
The company has raised € 47 million from top biotech investors.
ACE BioSciences' aim is to develop a new generation of vaccines through the use of proteomics.
Today, the company has around 20 highly skilled employees, most of whom are scientists working in vaccine research and development and an international network of partner organizations comprising the wider development team.
Plans for Future Growth
ACE BioSciences is built on a foundation of strong intellectual properties and an ambitious development program, and has assembled a strong management team, dedicated to continued growth. We have both the platform and the expertise to develop product candidates for the prevention and treatment of bacterial infections, through the use of proteomics. With a late-stage clinical product (Phase II) and strong follow up candidates, ACE BioSciences has established a promising product pipeline targeting attractive markets.
At ACE BioSciences, they combine proteomics-led target identification and vaccine focussed target validation to find novel drug targets. By extracting and analyzing the cell surface proteins used by bacterial pathogens to interact with and infect human hosts, they identify functional proteins and subsequently, evaluate them for their vaccine efficacy.
Their lead programs are vaccines against Campylobacter jejuni and Enterotoxigenic Escherichia coli (ETEC), the bacteria responsible for the most commonly reported bacterial cause of human gastroenteritis worldwide, as well as the major contributors to Travellers’ Diarrhoea.
Products in their pipeline to fight the challenge of Travellers’ Diarrhoea have the potential to be the first vaccine against Campylobacter, the first orally administered vaccine against ETEC, and the first combination vaccine against Campylobacter and ETEC. In addition, ACE BioSciences is working on a vaccine for Streptococcus pneumoniae, the bacterium responsible for pneumococcal disease, which will cover all indications in all age groups globally.
The annual global markets for the Campylobacter vaccine and the ETEC vaccine are estimated to be worth € 330 million and € 550 million respectively in 2008. The market for the Pneumococcal vaccine is worth billions of Euros.
ACE BioSciences A/S
Unsbjergvej 2a
5220 Odense SØ
Denmark
Proteomics company
